Prognostic Value of Genetic Mutations in Thyroid Cancer: A Meta-Analysis

Pak, Kyoungjune; Suh, Sunghwan; Kim, Seong Jang; Kim, In Joo

doi:10.1089/thy.2014.0241

Cited by 45 publications

(41 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its presence is diagnostic of thyroid cancer. Some studies suggest it may be associated with adverse disease characteristics and advanced disease stages [66][67][68][69][70][71][72]. Patients with recurrent or persistent PTC have a higher incidence of BRAF mutation [73].…”

Section: • Role Of Molecular Markers In Nodal Diseasementioning

confidence: 99%

Nodal Metastases in Thyroid Cancer: Prognostic Implications and Management

Wang

Ganly

2016

Future Oncol.

View full text Add to dashboard Cite

The significance of cervical lymph node metastases in differentiated thyroid cancer has been controversial and continues to evolve. Current staging systems consider nodal metastases to confer a poorer prognosis, particularly in older patients. Increasingly, the literature suggests that characteristics of the metastatic lymph nodes such as size and number are also prognostic. There is a growing trend toward less aggressive treatment of low-volume nodal disease. The aim of this review is to summarize the current literature and discuss prognostic and management implications of lymph node metastases in differentiated thyroid cancer.

show abstract

Section: • Role Of Molecular Markers In Nodal Diseasementioning

confidence: 99%

Nodal Metastases in Thyroid Cancer: Prognostic Implications and Management

Wang

Ganly

2016

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…Several recent publications note that ENE is an indicator of poor prognosis and survival 1823. The development of ENE is presumably a late event in the progression pathway for PTC,24 in contrast to BRAF mutation (recognized as a marker of enhanced potential for tumor invasion and metastasis25). In addition, ENE is associated with large tumor size 1726.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis

et al. 2016

Self Cite

View full text Add to dashboard Cite

PurposeThyroid cancer is the most common endocrine cancer and its incidence has continuously increased in the last three decades all over the world. We aimed to evaluate the prognostic value of extranodal extension (ENE) of thyroid cancer.Materials and MethodsWe performed a systematic search of MEDLINE (from inception to June 2014) and EMBASE (from inception to June 2014) for English-language publication. The inclusion criteria were studies of thyroid cancer that reported the prognostic value of ENE in thyroid cancer. Reviews, abstracts, and editorial materials were excluded, and duplicate data were removed. Two authors performed the data extraction independently.Results6 studies including 1830 patients were eligible for inclusion in the study. All patients included in the meta-analysis had papillary thyroid cancer (PTC). Recurrence-free survival was analyzed based on 3 studies. The pooled hazard ratio for recurrence was 2.01 [95% confidence interval (CI) 1.19–3.40, p=0.009]. Disease-specific survival was analyzed based on 3 studies with 973 patients. Patients of PTC with ENE showed 3.37-fold higher risk of death from the disease (95% CI 1.55–7.32, p=0.002).ConclusionENE should be considered to be a poor prognostic marker in thyroid cancer; such knowledge might improve the management of individual patients. This might facilitate the planning of appropriate ablation therapy and tailored patient follow-up from the beginning of treatment.

show abstract

“…The secondary end point was EFS. Data regarding disease-free survival (DFS), progression-free survival (PFS), recurrence-free survival (RFS) were obtained from the included studies, and were redefined as EFS, which was measured from the date of initiation of therapy to the date of recurrence or metastasis [42, 43]. …”

Section: Methodsmentioning

confidence: 99%

Prognostic value of microRNAs in osteosarcoma: a meta-analysis

Kim¹,

Goh

Lee

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

BACKGROUNDOsteosarcoma is the most common primary bone malignancy. We meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma.METHODSSources from MEDLINE (from inception to August 2016) and EMBASE (from inception to August 2016) were searched. Studies of osteosarcoma with results of miRNA and studies that reported survival data were included and two authors performed the data extraction independently. Any discrepancies were resolved by a consensus. The outcome was overall survival and event-free survival assessed using hazard ratios (HRs).RESULTSAfter reviewing the full text of 65 articles, 25 studies including 2,278 patients were eligible in this study. The pooled HR for deaths was 1.40 (95% confidence interval [CI] 1.01-1.94, p=0.04) with random-effects model (χ2=113.08, p<0.00001, I2=79%) for patients of osteosarcoma with lower expression of miRNA. However, the pooled HR for events was not significant (HR 0.97, 0.63-1.48, p=0.87, χ2=72.65, p<0.00001, I2=79%). In pathway analysis of miRNAs, miRNA449a, 199-5p, 542-5p have common target genes.CONCLUSIONSExpression level of miRNA in patients of osteosarcoma is important as a prognostic factor.

show abstract

Prognostic Value of Genetic Mutations in Thyroid Cancer: A Meta-Analysis

Abstract: Genetic mutations should be considered as a poor prognostic marker in thyroid cancer and may lead to better management of individual patients. However, the use of genetic mutations as prognostic markers should not be generalized, but individualized in the specific clinic setting.

Cited by 45 publications

References 44 publications

Nodal Metastases in Thyroid Cancer: Prognostic Implications and Management

Nodal Metastases in Thyroid Cancer: Prognostic Implications and Management

Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis

Prognostic value of microRNAs in osteosarcoma: a meta-analysis

Contact Info

Product

Resources

About